Amgen’s Repatha wins first PCSK9 OK in Japan

Carly Helfand

Amgen and the Sanofi and Regeneron team have been duking it out with their meds in the U.S., racing to ink payer deals in an effort to get ahead. But now, Amgen has the chance to get ahead start in another of the world's largest pharma markets.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS